Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler et al. · Nature Medicine · 2024
Cited by 102 works. doi:10.1038/s41591-023-02717-6 Open-access PDF
Authors
- Yasutoshi Kuboki
- Marwan Fakih
- John H. Strickler
- Rona D. Yaeger
- Toshiki Masuishi
- Edward Jae-Hoon Kim
- Christine M. Bestvina
- Scott Kopetz
- Gerald Steven Falchook
- Corey Jay Langer
- John C. Krauss
- Sonam Puri
- Panli Cardona
- Emily Chan
- Tracy Varrieur
- Lata Mukundan
- Abraham Anderson
- Qui Tran
- David S. Hong
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Cancer statistics, 2023
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer